



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ARCHIVIO ISTITUZIONALE
DELLA RICERCA

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

“Effects of Bacillus Velezensis D-18 on Health Status of European Seabass (*Dicentrarchus labrax*) Experimentally Challenged with *Vibrio harveyi*”

This is the final peer-reviewed author’s accepted manuscript (postprint) of the following publication:

Published Version:

Bignami, G., Monzón-Atienza, L., Leuzzi, D., Scicchitano, D., Candela, M., Gómez-Mercader, A., et al. (2025). “Effects of Bacillus Velezensis D-18 on Health Status of European Seabass (*Dicentrarchus labrax*) Experimentally Challenged with *Vibrio harveyi*”. PROBIOTICS AND ANTIMICROBIAL PROTEINS, version of record, 1-14 [10.1007/s12602-025-10833-7].

Availability:

This version is available at: <https://hdl.handle.net/11585/1037407> since: 2026-01-15

Published:

DOI: <http://doi.org/10.1007/s12602-025-10833-7>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

"Effects of *Bacillus velezensis* D-18 on health status of European Seabass (*Dicentrarchus labrax*) experimentally challenged with *Vibrio harveyi*"

Giorgia Bignami^{1,2}, Luis Monzón-Atienza², Daniela Leuzzi^{3,4}, Daniel Scicchitano^{3,4}, Marco Candela^{3,4}, Antonio Gómez-Mercader², Mouna Jlidi^{2,5}, Andrea Gustinelli¹, Perla Tedesco¹, Maria Letizia Fioravanti¹, Pedro Luis Castro², Felix Acosta^{2*}

¹ Department of Veterinary Medical Sciences, Alma Mater Studiorum – Università di Bologna, Bologna, Italy.

² Grupo de Investigación en Acuicultura (GIA), Instituto Ecoaqua, Universidad de Las Palmas de Gran Canaria, Spain.

³ Unit of Microbiome Science and Biotechnology (FaBit), Alma Mater Studiorum – University of Bologna, 40126, Bologna, Italy.

⁴ Fano Marine Center, the Inter-Institute Center for Research on Marine Biodiversity, Resources and Biotechnology, 61032, Fano, Italy.

⁵ Laboratory of Microbial Biotechnology and Engineering Enzymes (ILBMIE), Centre of Biotechnology of Sfax (CBS), University of Sfax, Tunisia.

*corresponding author: Felix Acosta Arbelo; felix.acosta@ulpgc.es

Abstract

In recent years, the use of probiotics as a possible alternative to antibiotics has generated a growing interest in the global aquaculture field. In this study, the probiotic *Bacillus velezensis* D-18 was evaluated for its potential protective effect against the marine pathogen *Vibrio harveyi*. The probiotic was administered through the diet of European seabass (*Dicentrarchus labrax*) for 30 days, followed by an *in vivo* challenge with *V. harveyi* to assess whether the D-18 strain could enhance host resistance to infection. Biofilm formation in tanks was also investigated to analyze its composition and if there are antagonistic interactions between the two bacterial species. From a histological perspective, significant changes were observed in intestinal morphological parameters after infection, the area and base of the villi appeared to increase in the probiotic-fed groups as did the number of goblet cells and in the serum antibacterial activity which was increased in the infected group that received the probiotic compared to baseline levels. The intestinal microbiome was also analyzed to monitor the composition and determine whether different diets before and after infection induced any changes. Although no significant differences were found in the metagenomics of the tank biofilm and the gut microbiome, mortality rates showed that the probiotic provided effective protection against the pathogen. These findings support the potential of *B. velezensis* D-18 as a viable alternative to antibiotics, particularly when included in the diet prior to disease onset.

Keywords: *Bacillus velezensis* D-18, probiotic, *Vibrio harveyi*, *Dicentrarchus labrax*, biofilm, gut microbiome

1. Introduction

In recent years, aquaculture has become the fastest-growing food production sector globally, playing a vital role in ensuring food safety and nutrition. Remarkably, for the first time in history, in 2022 aquaculture production of aquatic animals (94.4 million tonnes) surpassed capture fisheries, accounting for 51% of total production (FAO, 2024). These trends underscore the critical role aquaculture plays in global food systems and highlight the urgent need for sustainable practices. The FAO has recently called for a “Blue Transformation in action” in the The State of World Fisheries and Aquaculture (FAO, 2024), to enhance the efficiency, inclusiveness, resilience, and sustainability of aquatic food systems worldwide. At present, Gilthead seabream (*Sparus aurata*) and European seabass (*Dicentrarchus labrax*) are the most widely farmed species in the Mediterranean Sea, with a production volume of 520,000 tonnes and a market value of USD 2.58 billion in 2020 (FAO, 2024). Over 95% of the global production of Gilthead seabream and European seabass is derived from aquaculture, with 97% of this production occurring in Mediterranean countries (Zoli et al., 2023). In this regard, bacterial infections pose serious threats to bass and bream aquaculture (Mougin et al., 2021), with some more recently emerging bacterial diseases due to *Aeromonas veronii* and *Lactococcus garvieae* (Smyrli et al., 2019; Salogni et al., 2024), leading to large-scale mortality

54 events and severe economic losses. Among the various bacterial diseases affecting European seabass,
55 vibriosis - caused by several *Vibrio* species including *Vibrio anguillarum*, *V. harveyi*, *V. alginolyticus*,
56 *V. ordalii*, *V. parahaemolyticus* and *V. vulnificus* (Korun and Timur, 2008; Mougin et al., 2021) -
57 stands out as the most significant, impacting fish across all stages of the production cycle (Mougin et
58 al., 2021, Ina-Salwani et al., 2019). However, *V. harveyi* has recently emerged as a major concern in
59 European seabass aquaculture, and currently, no specific or effective prophylactic measures are
60 available to control this pathogen in this fish species (Mougin et al., 2021; Vendramin et al., 2016;
61 Firmino et al., 2019). In cases of severe infection, fish affected by *V. harveyi* display signs of
62 inappetence, lethargy and disorientation. Internally, pathological alterations include meningitis,
63 encephalitis, vasculitis, kidney necrosis, and damage to the liver and kidneys (Mohamad et al., 2019).
64 *Vibrio harveyi* is a Gram-negative, fermentative, rod-shaped bacterium that require sodium chloride
65 for growth and is motile via polar flagella (Farmer et al., 2015; Zhang et al., 2020). It is also a producer
66 of biofilm, a community of microorganisms adhering to and proliferate on biotic or abiotic surfaces
67 encased within extracellular polymeric substances (EPS) (Abebe, 2020; De Silva and Heo, 2023) and
68 able to give the pathogen the ability to persist in the environment, escaping the action of disinfectants
69 and antibiotics.

70 Historically, the predominant strategies for managing infections have involved chemical antibiotic
71 therapies (Assefa and Abunna, 2018; Torres-Maravilla et al., 2024). As in the case of other fish
72 bacterial infections, even those caused by *V. harveyi* are treated by administration of antibiotics in
73 the feed, but concerns about tissue residues and the emergence and spread of antibiotic resistance
74 have driven research toward alternative approaches to disease control, with a greater emphasis on
75 prevention rather than treatment (Zhang et al., 2020; Chen et al., 2020). Vaccination remains a widely
76 adopted strategy in aquaculture to induce long-lasting immune responses in farmed fish and provide
77 protection against pathogenic microorganisms. Most commercial vaccines are still based on
78 inactivated pathogens and are primarily administered via injection. In the field, autogenous vaccines
79 have been developed to control *Vibrio harveyi* in Gilthead seabream and European seabass production;
80 however, their practical application remain limited, and effective control still largely depends on
81 antimicrobial therapies (Smith et al., 2023).

82 Consequently, the search for compounds able to offer alternative strategies to combat pathogenic
83 bacteria while reducing antibiotic usage is considered a priority (Petit et al., 2024).

84 Among these, identifying probiotic bacteria that can both produce beneficial compounds and
85 effectively colonize aquaculture environments and antagonize potential pathogens circulating in the
86 system, represents a promising strategy for developing new products tailored to aquaculture (Petit et
87 al., 2024). Concerning the target host, probiotics are living microorganisms that, when administered
88 at appropriate doses, can promote a healthy balance of gut bacteria in animals (and humans). This can
89 result in various benefits such as preventing the invasion of harmful pathogens, improving digestion,
90 promoting growth, and increasing survival rates (Ntakirutimana et al., 2023). Probiotics also support
91 gut microbiome stability, improve water quality through bioremediation, and enrich zooplankton
92 nutrients (El-Saadoni et al., 2021). Various microorganisms, including yeast, fungi, and numerous
93 *Bacillus* species, are recognized for their probiotic functions and potential to replace antibiotics
94 (Iannitti and Palmieri, 2010); administered via food, they can antagonize intestinal pathogenic
95 bacteria and enhance disease resistance (Li et al., 2019, Khan et al., 2013, Monzón-Atienza et al.,
96 2022). In particular *Bacillus velezensis* was first described twenty years ago during extensive research
97 aimed at discovering bacterial strains capable of synthesizing new lipopeptides with surfactant or
98 antimicrobial properties (Ruiz-García et al., 2005). Concerning its possible application in
99 aquaculture, previous studies have isolated *B. velezensis* from waste-water at a Spanish farm (Ruiz-
100 García et al., 2005) and recent studies demonstrated the positive effects of *B. velezensis* strain D18,
101 (Monzón-Atienza et al., 2021), on the resistance of European seabass against *V. anguillarum* after
102 experimental challenge (Monzón-Atienza et al., 2021, 2022).

103 Main objectives of this study were to verify the effects of the probiotic *B. velezensis* D-18 on the
104 health status of European seabass maintained in a closed recirculation system and intraperitoneally

105 inoculated with the emerging pathogen *V. harveyi*. Survival rate, plasma antibacterial activity and gut
106 histology/morphology have been investigated. Furthermore, the composition of the tank biofilm and
107 of the fish intestinal microbiome pre- and post-challenge have been studied.

108 **2. Materials and methods**

109 **2.1 Bacterial strains**

110 The bacterial strain *Vibrio harveyi* ITT 281/14/B was from the repository of the Fish Pathology Unit
111 of the Department of Veterinary Medical Sciences of the University of Bologna (Unibo) and had been
112 isolated during a mortality outbreak in European seabass (*Dicentrarchus labrax*) farmed in Italy. It
113 had been previously identified by standard microbiological methods, including matrix-assisted laser
114 desorption/ionization time-of-flight mass spectrometry (Maldi-TOF, Bruker) and molecular analyses.
115 The probiotic *Bacillus velezensis* strain D-18 had been isolated, identified, and characterized earlier
116 by the Grupo de Investigación en Acuicultura (GIA), Instituto Ecoaqua, Universidad de Las Palmas
117 de Gran Canaria (ULPGC) (Monzón-Atienza et al., 2021).

118 To conduct the present trial, vials containing *V. harveyi* and *B. velezensis* and stored at -80 °C at
119 UNIBO and ULPGC bacterial collections respectively, were defrosted at about 4 °C on ice. Each
120 strain was aseptically cultured in sterile Erlenmeyer flasks containing 50 ml of brain heart infusion
121 (BHI; Cultimed, Panreac, Spain) supplemented with 1.5% sodium chloride (NaCl). Each flask,
122 inoculated with a single colony-forming unit (CFU) of each bacterial strain, was cultured following
123 classical microbiological techniques at 26 C ± 1 for 24 hours.

124

125 **2.2 Fish and housing**

126

127 A total of 240 European seabass (*Dicentrarchus labrax*) with an average body weight of 180 ± 10 g
128 were housed at the Marine Science and Technology Park at Universidad de las Palmas de Gran
129 Canaria (ULPGC), Spain. The University of Las Palmas's Ethical Committee accepted all
130 experimental protocol. Specimens selected following gross examination were determined to be
131 clinically healthy, exhibiting normal skin and gill coloration, no external lesions or infections, and no
132 documented history of parasitic infestation. For acclimatization, the experimental fish were randomly
133 distributed into twelve 500 L fiber-reinforced tanks (n = 20 fish/tank) in a closed water system at
134 22°C with continuous aeration, a 12:12 h photoperiod, and a water pH of 8 for two weeks. The fish
135 were fed daily at a regular rate calculated as 2 % of their biomass with a commercial diet (D-4
136 Optibream AE 3 P - Alterna, Skretting, Spain) of 4 mm diameter containing 40.5% fish protein and
137 18% fish oil. Before the beginning of the *V. harveyi* exposure, five individuals were randomly
138 selected to undergo standard microscopic and bacteriological tests to ensure they were not infected
139 with pathogenic bacteria. For each sampling, fish were anesthetized using clove oil overdose at
140 concentration of 0.5 mL/L (Guinama S.L., Spain, Ref. Mg83168), diluted in 100% alcohol (1:1).

141

142 **2.3 Feed preparation and experimental design**

143

144 The commercial European seabass feed served as the experimental control diet and as the basal diet
145 for the supplementation with *B. velezensis* D-18 (10⁶ CFU x feed g⁻¹), determined
146 spectrophotometrically at an optical density of 600 nm and by counting colony-forming units (CFU).
147 The incorporation process was conducted as follows. Briefly, the probiotic suspension was applied
148 using a spray bottle with the nozzle adjusted to release mist. The diet was mixed slowly in a drum
149 mixer and then air-dried on a clean bench for 12 hours, ensuring sterile conditions throughout the
150 process. The stock diet was stored at -20 °C, and daily rations were thawed at 4 °C before feeding.
151 The viability of the incorporated *B. velezensis* was assessed by vortexing 10 g of diet in 90 ml of
152 sterile PBS and preparing serial dilutions. 100 µl aliquots were cultured at 26 °C for 24 hours

153 following classical microbiological procedures. All fish were fed twice daily by hand for 30 days at
 154 a regular rate calculated as 2% of their biomass.
 155 After the two-week acclimation period, each tank, containing 20 fish fed with commercial diet, was
 156 randomly assigned to one of four experimental groups: Group Ctrl: 3 tanks as a control group - fish
 157 fed commercial diet throughout the trial period and not infected, only inoculated with 0,1 mL of
 158 sterile PBS at the day of the challenge; Group Bv: 3 tanks as another control group - fish fed diet with
 159 probiotics (*B. velezensis*) (10^6 CFU x feed g^{-1}) and not infected, only inoculated with 0.1 mL of sterile
 160 PBS at the day of the challenge; Group Ctrl-Ch: 3 tanks for challenge 1 - fish fed commercial diet for
 161 a month and intraperitoneally (IP) infected with *V. harveyi* and Group Bv-Ch: 3 tanks for challenge
 162 2 - fish fed diet with probiotics for a month and IP infected with *V. harveyi* (2×10^4 CFU x mL) (Fig.
 163 3).
 164 After one month of feeding each group with their own diet as per the experimental protocol, groups
 165 Ctrl-Ch and Bv-Ch were challenged and from this point, all groups were fed only a commercial diet
 166 until the end of the trial (Fig. 1).
 167




Fig. 1. Scheme of the experimental trial

168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184

2.4 Fish sampling

After 6 weeks from the beginning of the experimental trial (2 weeks for acclimation and 4 weeks of feeding period with experimental diets), all the fish were starved for 24 h. Three fish randomly collected from the Ctrl and Bv groups (only commercial diet and probiotic diet groups), after 30 days of feeding with experimental diets, and 14 days after challenge, humanely euthanised by administering a clove oil overdose at a concentration of 0.5 mL/L (Guinama S.L., Spain, Ref. Mg83168), diluted in 100% alcohol (1:1), achieving euthanasia within 1 minute and subjected to a wide set of analyses. After the challenge, the fish were observed and mortality was recorded daily. After 14 days of observation, the fish were sacrificed with an overdose of anaesthetic and 6 fish per group were sampled for analysis.

2.5 In vivo challenge test with *Vibrio harveyi*

185 The bacterial challenge was conducted as described in Monzón-Atienza et al. (2022). Briefly,
186 finalized the probiotic feeding trial, 3 individuals were ip injected with (2×10^4 CFU mL⁻¹) *V. harveyi*
187 strain live cells, to assure infectivity (Zhang et al., 2020). After the injection, fish were monitored
188 every 12 h over a six-day period for clinical signs of disease and mortality recorded. Upon death of
189 the fish, they were immediately inoculated into brain heart infusion (BHI; Cultimed, Panreac, Spain)
190 supplemented with 1.5% sodium chloride (NaCl) and thiosulfate citrate bile sucrose agar (TCBS,
191 Cultimed) plates from brain, kidney and spleen, to confirm the presence of the pathogen and reisolate
192 it.

193 With regard to the challenge of fish with bacterial strains, specimens were anesthetized with clove oil
194 (7 mL/100 lt.) and then intraperitoneally injected with 0.1 mL of PBS containing a suspension of *V.*
195 *harveyi* at the LD50 doses indicated by literature (Pujalte et al., 2003; Zhang et al., 2022) and, in the
196 case of the control groups (Ctrl and Bv), only with 0.1 mL of sterile PBS.

197 The described experiments complied with the European Union (86/609/EU), the Spanish Government
198 and the University of Las Palmas de Gran Canaria (Spain) guidelines for the use of laboratory animals
199 (OEBA-ULPGC 11/2024R1).

200

201 **2.6 Serum antibacterial activity**

202

203 Complete sets of samples were obtained at the end of the feeding trial on day 30 (Pre Challenge) and
204 at the final sampling (Post Challenge). Briefly, 3 fish for tank were sacrificed through anesthetic
205 (clove oil) overdose within 1 min and blood was collected from the caudal vein using 25 G needles
206 attached to a 2 mL syringe. One milliliter was loaded in a regular 1.5 mL Eppendorf tube and
207 centrifuged at 3000 rpm for 15 min to separate the serum. The collected serum was stored at - 20 °C
208 until further use.

209 In a round-bottom 96-well plate, in triplicates, 20 µl of plasma and 20 µl of *V. harveyi* (10^6 CFU/mL)
210 were incubated for 5h at 25°C. Hank's balanced salt solution or sterile PBS instead of plasma was
211 used for positive control. To each well, was added 25 µl of MTT (3-(4,5 dimethyl-2-yl)-2, 5-diphenyl
212 tetrazolium bromide, 1 mg/mL) and incubated for 10 min. at 25°C. After centrifuging at 2,000 x g for
213 10 min, the supernatant was removed and the pellet was dissolved in 200 µl of DMSO (dimethyl
214 sulfoxide). Finally, serum antibacterial activity was evaluated by measuring the absorbance of
215 dissolved format, which is produced by the metabolic activity of *V. harveyi* following the procedure
216 in Chung and Jeffries (1988). The antibacterial activity of plasma is shown in Figure 4. The
217 absorbance was recorded at 570 and 690 nm (final absorbance = Abs. 570 – Abs. 690). The percentage
218 bactericidal capacity is calculated by comparison with the reference sample (positive control).
219 Positive control means 100% of bacterial growth (0% of bactericidal activity).

220

221 **2.7 Gut microbiota and environmental biofilm composition assessment, samples collection,** 222 **DNA extraction and sequencing**

223


224 After sacrifice of the fish, the intestine of 3 fish for group, after 30 days of feeding with experimental
225 diets (before the challenge) at the end of trial (after the challenge), was removed from the visceral
226 mass and approximately 1.5 cm of the medial part was isolated. After opening, it was washed with
227 sterile PBS and the washed content collected in Eppendorf tubes containing 1 mL of RNAlater
228 (Thermo Fisher Scientific, Milan, Italy) for subsequent analyses. At the same time, in addition to the
229 fish gut, the biofilm was sampled from the walls of all the tanks by swabbing them with sterile cotton
230 swab Aptaca. The water level of each tank was briefly lowered by approximately 5 cm. Immediately
231 after taking the sample by swab, it was immersed in 10 mL of sterile PBS with 20 glass beads in the
232 laboratory and subjected to breaking by vortexing. 1 mL of sample was subjected to DNA extraction
233 with DNeasy Power Biofilm kit (QIAGEN, Hilden, Germany), while Total DNA was extracted with
234 briefly adaptation as previously described, using the protocol of DNeasy Blood & Tissue Kit
235 (QIAGEN).

236 To amplify the V3-V4 hypervariable region of the 16S rRNA gene, the 341F and 785R primers
237 (Klindworth et al., 2013) were used, together with Illumina adaptor overhang sequences and 2×
238 KAPA HiFi HotStart ReadyMix (KAPA Biosystems). The thermal cycle for this stage included an
239 initial denaturation phase at 95 °C for 3 minutes, 30 cycles of denaturation at 95 °C for 30 seconds,
240 annealing at 55 °C for 30 seconds, and extension at 72 °C for 30 seconds, followed by a final extension
241 step at 72 °C for 5 minutes. To purify PCR products for Illumina sequencing, the Illumina protocol
242 "16S Metagenomic Sequencing Library Preparation" was utilized, as described in earlier publications
243 (Musella et al., 2020; Biagi et al., 2019).
244 Sequencing was done on an Illumina MiSeq platform with a 2 × 250 bp paired-end technique,
245 following manufacturer's guidelines (Illumina, San Diego, CA). The raw sequences were processed
246 with the QIIME2 pipeline (Bolyen et al., 2019; <https://qiime2.org>). High-quality readings were
247 obtained by a filtering step with standard quality parameter and settled length parameter
248 (minimum/maximum = 350/550 bp) using DADA2 (Callahan et al., 2016), and also clustered into
249 Amplicon Sequence Variants (ASVs). VSEARCH algorithm (Rognes et al., 2016) was used to assign
250 taxonomy against the SILVA database (v138.2, Quast et al., 2013). The 16S rRNA gene was
251 sequenced from 12 intestinal content and 12 biofilm swabs samples, with three replicates collected
252 per dietary group. Following quality control and reads filtering, 10 intestinal samples were retained
253 for downstream analysis and 12 biofilm samples.
254 Alpha diversity was measured using `faith_pd`, `observed_features`, and `shannon_entropy`, whereas beta
255 diversity was determined by computing UniFrac distances, both weighted and unweighted, which
256 were then utilized as input for Principal Coordinates Analysis (PCoA). The Wilcoxon rank-sum test
257 was used to examine the significance of alpha diversity, while a permutation test with pseudo-F ratios
258 (adonis function) was utilized for beta diversity, considering the separation of data in principal
259 coordinate analysis (PCoA). Linear discriminant analysis effect Size, LefSe was then used to identify
260 discriminant taxa per each diet group (Segata, et al., 2011). P-values were considered significant if <
261 0.05. Statistical analysis of the microbiome were performed using R version 4.4.0 ([www.r-](http://www.r-project.org)
262 [project.org](http://www.r-project.org)) and specifically the following packages were involved: `vegan` (version 2.6-2, Oksanen et
263 al., 2022), `made4` (version 1.78.0, Culhane et al., 2005), `cluster` (version 2.1.6, Maechler et al., 2025),
264 `pairwiseAdonis` (version 0.4.1, Martinez et al., 2020), `RcppAlgos` (version 2.9.3, Wood et al., 2025),
265 `xlsx` (version 0.6.5, Dragulescu & Arendt, 2020), `matrixStats` (version 1.5.0, Bengtsson et al., 2025),
266 `RColorBrewer` (version 1.1-3, Neuwirth, 2022).

267 268 **2.8 Histological analysis**

269
270 Histological examination was conducted on six fish per tank. Intestinal samples were collected from
271 the mid-intestine (three segments) of fish from all the experimental groups. Tissues were fixed in
272 10% buffered formalin for 24 hours and processed using a Microm STP 120 Spin Tissue Processor
273 (STP120; Thermo Fisher Scientific). Paraffin-embedded sections were cut at 3 µm using a semi-
274 automated microtome (Jung Autocut 2055, Leica, Germany) and mounted on SuperFrost-Plus slides.
275 Sections were stained with Alcian Blue (pH 2.5) – Periodic Acid-Schiff (AB–PAS) following the
276 method of Martoja and Martoja-Pierson (1970), to differentiate between neutral and acidic mucins.
277 This staining protocol was also employed to assess mucosal fold morphology, including fold area,
278 height and width. Stained slides were scanned using a MoticEasyScan Pro digital scanner (Motic,
279 Xiamen, China) operated with Motic DS Assistant software (Motic VM V1 Viewer 2.0).
280 Representative images were selected for analysis. Image analysis was performed using the `analyzeSIS`®
281 software package (Image Pro Plus® v4.5.0.29; Media Cybernetics, Silver Spring, MD, USA),
282 calibrated using embedded scale bars. Three folds per section (three sections per fish) were analyzed.
283 Fold areas were manually delineated by tracing their perimeters, with the base defined by an
284 imaginary line connecting the junctions of adjacent anterior and posterior folds. Mucosal fold height
285 (from the villus apex to the base line), and fold width, were manually measured using the software's

286 built-in tools. Goblet cell area within each delineated fold was automatically quantified using the
287 eyedropper tool, and the percentage area was subsequently calculated.
288 The results from the morphometric analysis of histological sections (villus area, villus length, villus
289 width at base, number of goblet cells and goblet area / villus area ratio) were analysed by ANOVA,
290 with the critical value for statistical significance set at $p \leq 0.05$. Statistical analyses were carried
291 out using the Stata 19 software.
292



293
294
295 Fig. 2. Representative image of the intestinal measurement process in European seabass fed either a control (Ctrl) or probiotic (Bv)
296 diet, both before and after challenge (Ch). Mucosal fold area, height, and width were manually delineated. Goblet cell number and
297 area within each delineated fold were automatically quantified, and the percentage area was subsequently calculated.
298
299

300 3. Results

301 3.1 Survival

302 In the experimental challenge, as shown in figure 3, the relative survival percentage of the group fed
303 with *Bacillus velezensis* D-18 (Ctrl-Bv-Ch) was 50 %, compared to the control group (Ctrl-Ch), which
304 presented 27 % survival, and statistical analysis demonstrated strain D18 significantly increased fish
305 survival ($p = < 0.05$).
306
307
308




Fig. 3. Effect of the probiotic strain on European seabass survival rate against *V. harveyi*. Asterisks denote significant statistical differences: $p < 0.05$ (*) and $p < 0.001$ (**)

3.2 Antibacterial activity

The result of the antibacterial activity is shown in Figure 4. Briefly, it emerges that, compared to T0, the antibacterial activity increases in the Ctrl, Bv and Ctrl-Ch groups in crescendo. A significant difference is observed in the Bv-Ch group compared to T0 (Fig. 4).





Fig. 4. Antibacterial activity (%) of plasma from different experimental groups

3.3 Gut and biofilm bacterial communities


329 To determine whether probiotic supplementation and/or infection influenced the bacterial
 330 composition of the gut and/or biofilm, microbial communities from different sample types were
 331 analysed. Beta diversity was assessed using Principal Coordinate Analysis (PCoA) based on both
 332 unweighted and weighted (Fig. 5. a-b) UniFrac distance metrics. A significant separation in microbial
 333 community structure was observed among all groups ($p < 0.001$). Furthermore, alpha diversity, so the
 334 diversity within groups, differed significantly across groups, as indicated by three diversity metrics:
 335 Faith's Phylogenetic Diversity, Observed Features, and Shannon Entropy (Fig. 5. c). No significant
 336 variations were found for the alpha diversity indices among groups of the same sample types (i.e. fish
 337 gut microbiota or biofilm microbiota assessed in different conditions).
 338
 339



340
 341 Fig. 5. Beta and alpha diversity of gut and biofilm swab microbial community of fishes tank fed with different diet. (a-b) Beta
 342 diversity of biofilm and gut of European seabass fed with different diets. PCoA based on weighted and unweighted UniFrac distances
 343 between microbiota layout of gut content (G) and cage biofilm (B). Samples are significantly separated (permutation test with
 344 pseudo-F ratios Adonis; $p < 0.001$). (c) Boxplots show alpha diversity values measured by Faith's Phylogenetic Diversity (faith_pd),
 345 observed features and Shannon entropy. All metrics displayed significant variation (Kruskal–Wallis test $p < 0.05$) of alpha diversity
 346 among groups [diet Ctrl, Bv, Ctrl-Ch, Bv-Ch, in gut (G) and biofilm (B)].
 347

348 To further investigate the microbial composition, different phylogenetic levels were analyzed. As
 349 shown in figure 6.a, at the phylum level, the gut microbiota was predominantly composed by
 350 Pseudomonadota, Bacillota, Bacteroidota, Actinomycetota, and Spirochaetota phyla, mean
 351 abundance and standard deviation are reported in Supplementary Table 1. In contrast, the biofilm
 352 swabs exhibited a higher relative abundance of Bacteroidota, Pseudomonadota, Chloroflexota,
 353 Verrucomicrobiota, and Planctomycetota (Supplementary Table 2). Analysis was also conducted at
 354 the family level for both intestinal and biofilm samples. Concerning gut composition,

355 Enterobacteriaceae, Alicyclobacillaceae, Flavobacteriaceae, Saprospiraceae, Spirochaetaceae,
 356 Lactobacillaceae, and Streptococcaceae were the mainly present families in Ctrl group. Main families
 357 in Ctrl-Bv group were Enterobacteriaceae, Alicyclobacillaceae, Flavobacteriaceae, Spirochaetaceae,
 358 Lactobacillaceae, Streptococcaceae, Vibrionaceae, and Lachnospiraceae. Ctrl-Ch group was mainly
 359 composed of Spirochaetaceae, Lactobacillaceae, Streptococcaceae, and Lachnospiraceae. Group Ctrl-
 360 Bv-Ch has as main families Enterobacteriaceae, Flavobacteriaceae, Spirochaetaceae,
 361 Lactobacillaceae, Streptococcaceae, Pseudomonadaceae, and Lachnospiraceae, mean and standard
 362 deviation of the most represented families per group with the respective standard deviation are
 363 reported in Supplementary Table 3. Regarding the biofilm microbiota at the family level,
 364 Chitinophagaceae, Flavobacteriaceae, Hyphomonadaceae, Paracoccaceae, Pirellulaceae,
 365 Rubritaleaceae, and Saprospiraceae are the main families present in all groups (Ctrl, Ctrl-Bv, Ctrl-
 366 Ch, Ctrl-Bv-Ch) with the respective mean and standard deviation, described in Supplementary Table
 367 4. To more thoroughly assess taxonomic differences at the family level, Linear Discriminant Analysis
 368 Effect Size (LEfSe) was performed on both intestinal and biofilm samples. In the gut, Saprospiraceae
 369 in the Ctrl group emerged as the only significant discriminant taxon (Fig. 6.b). For the biofilm
 370 samples, Phycisphaeraceae and Oxalobacteraceae were identified as discriminant taxa in the Ctrl-Bv
 371 group. The Ctrl group was characterized by significant higher abundance of
 372 Thermoanaerobaculaceae, Arcobacteraceae, Sphingomonadales_DEV007, Moraxellaceae and
 373 Verrucomicrobiales_199 families. Finally, the Ctrl-Ch group showed significant enrichment of
 374 Propionibacteriaceae, Steroidobacterales_178 family, Pseudomonadaceae, and Sphingomonadaceae
 375 (Fig. 6.c).



376
 377
 378 Fig. 6. Microbiota composition of tank biofilm and gut samples of European seabass fed with different diet. (a) Barplot summarizing
 379 the microbiota composition at phylum level of tank biofilm swab (B) and fishes' gut (G) divided in study groups (Ctrl, Bv, Ctrl-Ch,
 380 Bv-Ch). (b-c) Lefse analysis performed on gut (b) and biofilm (c) composition with LDA score threshold of 1.5 and a $p < 0.05$.
 381

382 3.4 Histological analysis

383
 384 Histological analysis of the midgut samples of European seabass feed experimental diets revealed
 385 significant changes in goblet cells size and density and intestinal fold morphology following probiotic
 386 supplementation and challenge.
 387 The area of goblet cells decreased significantly after the challenge in both the commercial diet group
 388 (Ctrl/Ctrl-Ch; $p = 0.0156$) and the probiotic-fed group (Bv/Bv-Ch; $p = 0.0006$) (Fig. 7). In contrast,
 389 the number of goblet cells increased post-challenge only in the commercial diet group (Ctrl; $p =$

390 0.0002), while the probiotic-fed group (Bv) exhibited a higher baseline count compared to Ctrl ($p =$
 391 0.0002) (Fig. 7).




Fig. 7. Goblet cell area and density relative to the fold area in the intestine of European seabass (*D. labrax*) fed control (Ctrl) or probiotic (Bv) diets, pre- and post-challenge.

392
 393
 394
 395
 396 Fold measurements showed consistent post-challenge increases: length expanded in both the
 397 commercial diet (Ctrl-Ch; $p < 0.0001$) and probiotic-fed (Bv-Ch; $p = 0.0001$) groups (Fig. 8),
 398 while base width increased in all challenged groups (Ctrl-Ch/Bv-Ch; $p < 0.0001$), with Bv-Ch
 399 maintaining a significantly wider base than Ctrl-Ch ($p = 0.0104$) (Fig. 8). Notably, the probiotic-
 400 fed group (Bv) displayed wider fold bases at baseline compared to Ctrl ($p < 0.0001$).
 401




Fig. 8. Fold length and fold base width in the intestine of European seabass (*D. labrax*) fed control (Ctrl) or probiotic (Bv) diets, pre- and post-challenge.

402
 403
 404
 405
 406 Fold area similarly increased post-challenge in all groups ($p < 0.0001$), with Bv showing larger
 407 baseline areas than Ctrl ($p < 0.0001$) (Fig. 9). Regarding the fold area, after the challenge it was
 408 increased in both cases (without probiotics and with probiotics) ($p = 0.0000$). The group fed with
 409 commercial diet (Ctrl) were found to have a smaller fold area compared to the groups fed only with
 410 probiotic diet (Ctrl-Bv) ($p = 0.0000$) (Fig. 9).




Fig. 9. Fold area in European seabass (*D. labrax*) fed control (Ctrl) or probiotic (Bv) diets, pre- and post-challenge.

411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451

4. Discussion

Recent studies have further highlighted the probiotic potential of *Bacillus velezensis* in aquaculture systems. For instance, Abdelsamad et al. (2024) demonstrated that dietary supplementation with *B. velezensis* significantly enhanced growth performance, antioxidant enzyme activity, and immune-related gene expression in Pacific white shrimp (*Litopenaeus vannamei*). These findings reinforce the immunomodulatory role of *B. velezensis* across diverse aquaculture species. Moreover, Hrabar et al. (2025) isolated *B. velezensis* from the gut microbiota of Mediterranean fish and confirmed its biosynthetic potential through whole genome sequencing. The isolate induced a strong pro-inflammatory cytokine response in peripheral blood leukocytes, suggesting its capacity to prime host immunity. This aligns with our findings of increased goblet cell density and antibacterial activity in European seabass fed with *B. velezensis* D-18. In addition, paraprotiotic forms of *B. velezensis* have shown promise in modulating both innate and adaptive immune responses in vitro and in vivo (Lee et al., 2024). These heat-killed preparations may offer a safe and effective alternative in scenarios where live probiotics are not feasible. Collectively, these recent advances support the broader application of *B. velezensis* as a multifunctional probiotic in aquaculture, capable of enhancing host immunity, improving gut morphology, and potentially reducing reliance on antibiotics.

The probiotic *B. velezensis* strain D-18 has been shown to effectively combat pathogenic diseases such as vibriosis in both marine and freshwater fish (Thurlow et al., 2019; Wang et al., 2019; Monzón-Atienza et al., 2021; 2022). Several review articles have highlighted that the use of probiotics in aquaculture offers numerous benefits, such as enhanced growth performance, disease resistance, immune response, overall health, and balanced fish physiological functions (El-Saadony et al., 2021). With the increasing demand for environmentally friendly additives, *Bacillus* spp., along with other probiotics used in aquaculture, have attracted growing interest from researchers due to their significant immunomodulatory effects and role in disease prevention (Amoah et al., 2021; Monzón-Atienza et al., 2022), also because, in recent years, the use of antibiotic treatments has come under scrutiny and been restricted in several countries due to their bioaccumulative properties and the growing issue of antimicrobial resistance, which poses significant risks to both human and animal health (Santos and Ramos, 2018). It is therefore urgent to find alternatives to antibiotics that can fight pathogens. Some of the alternatives to the excessive use of antibiotics in order to deal with pathogens in aquaculture are vaccination and the use of probiotic strains (Torres-Maravilla et al., 2024). In fish, probiotics can be administered through various methods, including bath immersion, suspension, and dietary supplementation. Oral delivery of probiotics has been found to enhance immunity and provide better protection compared to bath immersion (Taoka et al., 2006). In fact, the effectiveness of probiotic microorganisms largely depends on their ability to survive and multiply within the host. For optimal impact, the bacteria should remain metabolically stable and active in the product and endure passage through the intestinal tract in substantial numbers. A feed's probiotic effect is likely to achieve the desired results only if it contains at least 10^6 to 10^7 live probiotic bacteria per gram or

452 milliliter (Fečkaninová et al., 2017). In this study, every two days, *B. velezensis* D-18 inoculum was
453 prepared and aseptically supplemented to the commercial diet. There are numerous studies on
454 probiotics used in aquaculture, *Bacillus* spp. have seen growing and widespread application in
455 aquaculture as probiotics. Their innate advantages are more pronounced compared to non-spore-
456 forming bacterial strains (Meidong et al., 2018). Most *Bacillus* strains are both aerobic and
457 facultatively anaerobic, allowing them to thrive in diverse environments and effectively compete with
458 potential pathogens (Cutting, 2011). The ability of *Bacillus* species to form endospores enables them
459 to survive under extreme environmental stresses and offers biological solutions to formulation and
460 preservation challenges in large-scale industrial production. This study investigated how the probiotic
461 *B. velezensis* affects European seabass by feeding it for 30 days and then challenging the fish with *V.*
462 *harveyi*—an emerging pathogen in Mediterranean mariculture (Vendramin et al., 2016; Zhang et al.,
463 2020). The survival rates we recorded at the end of the trial demonstrate that the probiotic *B.*
464 *velezensis* D-18 has a positive effect on the fish infected by the pathogen, in fact the group fed with
465 this probiotic had a survival of 50%, statistically higher than the survival of 27% registered in the
466 group fed only with commercial diet (fig. 2), as also indicated in a recent study by Li et al. (2019),
467 who used a different strain of *B. velezensis* against *V. harveyi* as a pathogen evaluating the efficacy
468 of this probiotic as resistance, growth and immunity to the hybrid fish *Epinephelus*. Probiotics can
469 modulate various innate immune mechanisms in fish, including enhancing phagocytic activity,
470 stimulating the production of antimicrobial peptides, and promoting the expression of cytokines
471 involved in inflammation and immune regulation (Monzón-Atienza et al., 2022). These effects
472 contribute to a more responsive and balanced immune system, improving the host's ability to resist
473 pathogenic infections. Our results suggest that *B. velezensis* D-18 may act through some of these
474 pathways; however, the precise mechanisms remain to be elucidated. Further studies are needed to
475 fully characterize how this probiotic interacts with host immune components and to explore its long-
476 term effects under commercial aquaculture conditions.

477 A fundamental aspect concerns the ability of this pathogen to produce biofilm, in fact the release of
478 *V. harveyi* from biofilms into the rearing water or its contact with the walls of aquaculture tanks may
479 elevate bacterial prevalence in fish, increasing the risk of vibriosis outbreaks. Therefore, monitoring
480 *V. harveyi* abundance in the surrounding environment, such as rearing water and biofilms, could serve
481 as an indicator of European seabass contamination and the likelihood of vibriosis outbreaks. For this
482 reason, in this study we considered both the survival of the fish after the challenge and the
483 composition of the intestinal microbiome and the bacterial composition of the tank biofilm. These
484 types of pathogenic bacteria also can survive independently of a host and readily proliferate within
485 aquaculture systems. Although their transmission strategies are not yet fully understood, it is
486 estimated that approximately 90% of bacteria persist through biofilm formation. This process has
487 been widely recognized as a key mechanism for the survival of pathogenic bacteria (Cai and Arias,
488 2017; Tasneem et al., 2018). In this study we also wanted to analyze environmental biofilm as both
489 probiotics and pathogenic bacteria can produce it as a survival strategy in the aquaculture
490 environment. Identifying probiotic bacteria capable of both producing bioactive compounds and
491 colonizing aquaculture environments represents a promising strategy for developing new products
492 specifically designed for use in aquaculture. Bacteria from the *Bacillus* genus are well known for their
493 antibacterial and antibiofilm properties, rapid growth rate, low nutritional requirements, and tolerance
494 to anaerobic conditions (Petit et al., 2024). The metagenomic results of the biofilm removed from the
495 walls of the tanks show no differences in the different tanks/groups, the Phylum Bacteroidota is
496 present both in the intestine and in the tanks. This shows that in a short period of treatment as in our
497 case, the biofilm remains a dangerous reservoir of potentially pathogenic bacteria that can remain in
498 the environment in a stable way over time.

499 A strong correlation exists between gut microbiota composition and the overall health status of fish.
500 An early theory suggested that probiotics played a role in competitively excluding infectious
501 pathogens. Upon entering the host's digestive tract, these beneficial microorganisms were thought to
502 either produce inhibitory compounds or compete with pathogens for adhesion sites, nutrients,

503 chemicals, or energy sources, thereby hindering their growth or activity (Merrifield et al., 2010; El-
504 Saadony et al., 2021). The gut microbiota—widely recognized for its crucial role in immune function,
505 maintaining homeostasis, enhancing intestinal health, and promoting growth and overall well-
506 being—has become a central focus of research. Cahill (1990) reported that bacteria present in the
507 aquatic environment influence the composition of gut microbiota in aquatic organisms, and this
508 interaction is reciprocal. The gastrointestinal tract of fish harbors a diverse community of resident
509 microorganisms, collectively known as the microbiota, which have co-evolved with the host in a
510 symbiotic relationship, contributing to metabolic functions and defense against pathogenic infections
511 (Vargas-Albores et al., 2021). Numerous studies have linked beneficial shifts in the gut microbiota to
512 probiotic supplementation (Amoah et al., 2021). Our results show that there are no major changes in
513 the composition of the intestinal microbiome after administration of probiotic for a month, nor for the
514 biofilm of the tanks (Fig. 5-6). This aspect is very interesting because it shows that *B. velezensis*
515 works, since the fish is more resistant after having taken it, despite the fact that the microbiome is
516 almost stable. Probably results that indicate more important changes can be obtained after a more
517 prolonged administration over time. In the present study, since the fish showed a higher survival after
518 the challenge, it can be deduced that the probiotic *Bacillus* strains improve and maintain a balanced
519 intestinal microflora, thus enhancing the health and well-being of European seabass as already
520 demonstrated in a work with Nile tilapia (Kuebutornye et al., 2020).

521 We also evaluated the plasma bactericidal activity and histologically analyzed the intestinal villi and
522 related goblet cells. Regarding the immune parameters analyzed, our results about bactericidal
523 activity show that there is a statistically significant difference between the initial group (T0) and the
524 probiotic-fed and infected group, this confirms what was stated in studies in humans that have
525 demonstrated that administering probiotics from the *Bacilli* class significantly enhances bactericidal
526 activity by promoting the production of bacteriostatic molecules such as hydrogen peroxide and lactic
527 acid (Abdul-Rahim et al., 2021). These molecules exhibit potent antimicrobial effects against a broad
528 spectrum of pathogens, including various multi-antibiotic-resistant species. The bactericidal activity
529 (Fig. 4) observed after the challenge confirms a greater activity of the infected group fed with *B.*
530 *velezensis* compared to the control, as also demonstrated by the study by Monzón-Atienza et al.
531 (2022) who carried out a test to verify the effects of *B. velezensis* with a challenge with *V.*
532 *anguillarum*. Moreover, in an activated state, such as that induced by probiotics, goblet cells increase
533 in both number and size, and bactericidal activity levels also tend to increase (Castejón et al., 2021).
534 The modulation of goblet cell dynamics—where probiotic-fed fish maintained higher baseline cell
535 counts but exhibited reduced cell area post-challenge—may indicate a strategic trade-off between
536 mucus secretion efficiency and epithelial coverage. This aligns with findings that *Bacillus*-derived
537 probiotics stimulate goblet cell proliferation while optimizing mucus composition for pathogen
538 exclusion (Khojasteh, 2021; Tonetti et al., 2024). Such adaptations are particularly relevant in RAS,
539 where high stocking densities and biofilm formation increase *Vibrio* transmission risks (Pirarat et al.,
540 2011; Monzón-Atienza et al., 2024). Additionally, the application of histological assays is discussed
541 as a reliable method for assessing fish welfare, with particular attention given to gut morphology as
542 an indicator of nutrient absorption capacity and immune responsiveness (De Marco et al., 2023). The
543 increase in fold dimensions (length and base width) aligns with previous studies demonstrating that
544 probiotics like *B. velezensis* promote intestinal absorptive surface area, thereby improving nutrient
545 utilization and disease resistance (Ramos et al., 2017). Notably, the wider fold base in probiotic-fed
546 fish post-challenge could reflect an adaptive response to *V. harveyi* infection, as intestinal structural
547 integrity is critical for mitigating pathogenic colonization (Kuebutornye et al., 2020).

548 Collectively, these findings support the potential of *B. velezensis* to enhance European seabass health
549 in RAS environments by reinforcing intestinal morphology and goblet cell-mediated defenses. Future
550 studies could explore the probiotic's impact on *V. harveyi* biofilm disruption and immune gene
551 expression to elucidate additional protective mechanisms.

552 553 **5. Conclusion**

554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569

In conclusion, this study provides an assessment of the characteristics of the European seabass gut microbiome and environmental biofilm composition after one month of administration of *Bacillus velezensis* strain D-18, contributing to provide data that extend previous studies. Although further complex mechanisms, such as quorum sensing interference and competitive exclusion within the gut microbiota, our results provide compelling evidence of the increased resistance of European seabass to *V. harveyi* and highlight its potential as an effective probiotic agent to improve disease resistance in intensively farmed European seabass, as confirmed by the increase in the number of goblet cells and antibacterial activity in the probiotic-fed group. Although no changes occurred in the gut microbiome and bacterial content of the biofilm in the tanks, the challenge is to be able to prepare fish from intensive farms through a change in the intestinal microbiome to be able to achieve such resistance that when the disease arrives they can survive without the use of emergency interventions with antibiotics. Further studies will be needed to investigate the mechanisms of the probiotic at the intestinal and environmental biofilm levels, to verify the actual link between increased resistance and changes in the intestinal and environmental microbiome.

570 **Ethics approval**

571
572
573
574
575
576
577

All procedures conducted with the fish agreed to the guidelines of the European Union Council (86/609/EU) and Spanish legislation (RD 53/2013) and were approved by the Bioethical Committee of the University of Las Palmas de Gran Canaria (OEBA-ULPGC-11/2024R1). Notably, the number of animals used was determined following a highly restricted f-size a priori effect established at the 0.05 α -error probability on the power analysis accomplished.

578 **Acknowledgments**

579
580
581
582
583
584

The authors gratefully acknowledge the support provided by the PROFISH: TNA AQUAEXCEL Project (28740). This research was made possible through the funding and infrastructure made available by the project AQUAEXEL and Marine Scientific Park of University of Las Palmas de Gran Canaria, which played a crucial role in facilitating the experimental work and data collection. We extend our sincere thanks for their valuable contribution to the advancement of this study.

585 **References**

- 586
- 587 Abdelsamad, A.E.M., Said, R.E.M., Assas, M., Gaafar, A.Y., Hamouda, A.H., Mahdy, A., 2024.
588 Effects of dietary supplementation with *Bacillus velezensis* on the growth performance, body
589 composition, antioxidant, immune-related gene expression, and histology of Pacific white shrimp,
590 *Litopenaeus vannamei*. BMC Veterinary Research 20(1):368. [https://doi.org/10.1186/s12917-024-](https://doi.org/10.1186/s12917-024-04207-4)
591 [04207-4](https://doi.org/10.1186/s12917-024-04207-4)
- 592
- 593 Abebe, G.M., 2020. The role of bacterial biofilm in antibiotic resistance and food contamination.
594 International Journal of Microbiology (281). <https://doi.org/10.1155/2020/1705814>
- 595
- 596 Acosta, F., Montero, D., Izquierdo, M., Galindo-Villegas, J., 2021. High-level biocidal products
597 effectively eradicate pathogenic γ -proteobacteria biofilms from aquaculture facilities. Aquaculture
598 532:736004. <https://doi.org/10.1016/j.aquaculture.2020.736004>
- 599
- 600 Amoah, K., Dong, X., Tan, B., Zhang, S., Chi, S., Yang, Q., Liu, H., Yang, Y., Zhang, H., 2021.
601 Effects of three probiotic strains (*Bacillus coagulans*, *B. licheniformis* and *Paenibacillus polymyxa*)
602 on growth, immune response, gut morphology and microbiota, and resistance against *Vibrio harveyi*
603 of northern whittings, *Sillago sihama* Forssk'al (1775). Animal Feed Science and Technology 277,
604 114958. <https://doi.org/10.1016/j.anifeedsci.2021.114958>
- 605
- 606 Assefa, A., Abunna, F., 2018. Maintenance of Fish Health in Aquaculture: Review of
607 Epidemiological Approaches for Prevention and Control of Infectious Disease of Fish. Veterinary
608 Medicine International 5432497. <https://doi.org/10.1155/2018/5432497>
- 609
- 610 Austin, B., 2010. Vibrios as causal agents of zoonoses. Veterinary Microbiology 140, 310–317.
611 <https://doi.org/10.1016/j.vetmic.2009.03.01>
- 612
- 613 Bengtsson, H., Baath R., 2025. matrixStats: Functions that Apply to Rows and Columns of Matrices
614 (and Vectors). R package version 1.5.0.
615 <https://cran.rproject.org/web/packages/matrixStats/index.html>
- 616
- 617 Biagi, E., D'Amico, F., Soverini, M., Angelini, V., Barone, M., Turrone, S., Rampelli, S., Pari, S.,
618 Brigidi, P., Candela, M., 2019. Faecal bacterial communities from Mediterranean loggerhead sea
619 turtles (*Caretta caretta*). Environmental Microbiology Report 11, 361–371.
620 <https://doi.org/10.1111/1758-2229.12683>
- 621
- 622 Bolyen, E., Rideout, J.R., Dillon, M.R., Bokulich, N.A., Abnet, C.C., Al-Ghalith, G.A., Alexander,
623 H., Alm, E.J., Arumugam, M., Asnicar, F., Bai, Y., Bisanz, J.E., Bittinger, K., Brejnrod, A., Brislawn,
624 C.J., Brown, C.T., Callahan, B.J., Caraballo-Rodríguez, A.M., Chase, J., Cope, E.K., Da Silva, R.,
625 Diener, C., Dorrestein, P.C., Douglas, G.M., Durall, D.M., Duvall, C., Edwardson, C.F., Ernst, M.,
626 Estaki, M., Fouquier, J., Gauglitz, J.M., Gibbons, S.M., Gibson, D.L., Gonzalez, A., Gorlick, K., Guo,
627 J., Hillmann, B., Holmes, S., Holste, H., Huttenhower, C., Huttley, G.A., Janssen, S., Jarmusch, A.K.,
628 Jiang, L., Kaehler, B.D., Kang, K. Bin, Keefe, C.R., Keim, P., Kelley, S.T., Knights, D., Koester, I.,
629 Kosciolk, T., Kreps, J., Langille, M.G.I., Lee, J., Ley, R., Liu, Y.X., Lofffield, E., Lozupone, C.,
630 Maher, M., Marotz, C., Martin, B.D., McDonald, D., McIver, L.J., Melnik, A. V., Metcalf, J.L.,
631 Morgan, S.C., Morton, J.T., Naimey, A.T., Navas-Molina, J.A., Nothias, L.F., Orchanian, S.B.,
632 Pearson, T., Peoples, S.L., Petras, D., Preuss, M.L., Priesse, E., Rasmussen, L.B., Rivers, A.,
633 Robeson, M.S., Rosenthal, P., Segata, N., Shaffer, M., Shiffer, A., Sinha, R., Song, S.J., Spear, J.R.,
634 Swafford, A.D., Thompson, L.R., Torres, P.J., Trinh, P., Tripathi, A., Turnbaugh, P.J., Ul-Hasan, S.,
635 van der Hooft, J.J.J., Vargas, F., Vázquez-Baeza, Y., Vogtmann, E., von Hippel, M., Walters, W.,

636 Wan, Y., Wang, M., Warren, J., Weber, K.C., Williamson, C.H.D., Willis, A.D., Xu, Z.Z., Zaneveld,
637 J.R., Zhang, Y., Zhu, Q., Knight, R., Caporaso, J.G., 2019. Reproducible, interactive, scalable and
638 extensible microbiome data science using QIIME 2. Nature Biotechnology
639 <https://doi.org/10.1038/s41587-019-0209-9>
640

641 Branda, S.S., Vik, Å., Friedman, L., Kolter, R., 2005. Biofilms: the matrix revisited. Trends in
642 Microbiology 13(1):20-6. <https://doi.org/10.1016/j.tim.2004.11.006>
643

644 Cahill, M.M., 1990. Bacterial flora of fishes - A Review. Microbial Ecology 19:21-41.
645

646 Cai, W., Arias, C.R., 2017. Biofilm formation on aquaculture substrates by selected bacterial fish
647 pathogens. Journal of Aquatic Animal Health 29:95-104 doi:
648 <https://doi.org/10.1080/08997659.2017.1290711>
649

650 Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J.A., Holmes, S.P., 2016.
651 DADA2: High-resolution sample inference from Illumina amplicon data. Nature Methods 13, 581-
652 583. <https://doi.org/10.1038/nmeth.3869>
653

654 Castejón, P., Cabas, I., Gómez, V., Chaves-Pozo, E., Cerezo-Ortega, I., Morinigo, M.A., Martínez-
655 Manzanares, E., Galindo-Villegas, J., García-Ayala, A., 2021. Vaccination of gilthead seabream after
656 continuous xenoestrogen oral exposure enhances the gut endobolome and immune status via GPER1,
657 Frontiers in Immunology 12, 742827, <https://doi.org/10.3389/fimmu.2021.742827>
658

659 Chen, J., Lu, Y., Ye, X., Emam, M., Zhang, H., Wang, H., 2020. Current advances in *Vibrio harveyi*
660 quorum sensing as drug discovery targets. European Journal of Medicinal Chemistry 207, 112741.
661 <https://doi.org/10.1016/j.ejmech.2020.1127417>
662

663 Chung, S.G., Jeffries, A.H., 1988. A novel assay to detect macrophage bactericidal activity in fish ;
664 factors influencing the killing of *Aeromonas salmonicida*. Journal of Fish Diseases, Wiley Online
665 Library.
666

667 Culhane, A.C., Thioulouse, J., Perrière, G., Higgins, V.J., 2005. made4: Multivariate analysis of gene
668 expression data. R package version 1.78.0. Bioconductor. <http://bioconductor.org/packages/made>
669

670 Cutting, S.M., 2011. *Bacillus* probiotics. Food Microbiology 28, 214-220.
671 <https://doi.org/10.1016/j.fm.2010.03.007>
672

673 Dadar, M., Dhama, K., Vakharia, V.N., Hoseinifar, S.H., Karthik, K., Tiwari, R., Khandia, R.,
674 Munjal, A., Salgado-Miranda, C., Joshi, S.K., 2017. Advances in aquaculture vaccines against fish
675 pathogens: global status and current trends. Reviews in Fisheries Science & Aquaculture 25, 184-
676 217. DOI: <https://doi.org/10.1080/23308249.2016.1261277>
677

678 De Marco, G., Cappello, T., Maisano, M., 2021. Histomorphological Changes in Fish Gut in
679 Response to Prebiotics and Probiotics Treatment to Improve Their Health Status: A Review. Animals
680 13, 2860. <https://doi.org/10.3390/ani13182860>
681

682 De Silva, L.A.D.S., Heo, G-J., 2023. Biofilm formation of pathogenic bacteria isolated from aquatic
683 animals. Vol.:(0123456789)1 3 Archives of Microbiology 205:36 <https://doi.org/10.1007/s00203-022-03332-8>
684
685

686 Dragulescu, A.A., Arendt, C., 2020. xlsx: Read, Write, Format Excel 2007 and Excel
687 97/2000/XP/2003 Files. R package version 0.6.5. <https://CRAN.R-project.org/package=xlsx>
688

689 El-Saadony, M.T., Alagawany, M., Patra, A.K., Kar, I., Tiwari, R., Dawood, M.A.O., Dhama, K.,
690 Abdel-Latif, H.M.R., 2021. The functionality of probiotics in aquaculture: An overview. *Fish and*
691 *Shellfish Immunology* 117, 36–52. <https://doi.org/10.1016/j.fsi.2021.07.007>
692

693 EU, 2006. Ban on antibiotics as growth promoters in animal feed enters into effect. Regulation.
694 Brussels, Belgium, 1.
695 [https://ec.europa.eu/commission/presscorner/detail/en/IP_05_1687#:~:text=An%20EU-](https://ec.europa.eu/commission/presscorner/detail/en/IP_05_1687#:~:text=An%20EU-wide%20ban%20on%20the%20use%20of%20antibiotics,phasing%20out%20of%20antibiotics%20used%20for%20non-medicinal%20purposes)
696 [wide%20ban%20on%20the%20use%20of%20antibiotics,phasing%20out%20of%20antibiotics%20](https://ec.europa.eu/commission/presscorner/detail/en/IP_05_1687#:~:text=An%20EU-wide%20ban%20on%20the%20use%20of%20antibiotics,phasing%20out%20of%20antibiotics%20used%20for%20non-medicinal%20purposes)
697 [used%20for%20non-medicinal%20purposes](https://ec.europa.eu/commission/presscorner/detail/en/IP_05_1687#:~:text=An%20EU-wide%20ban%20on%20the%20use%20of%20antibiotics,phasing%20out%20of%20antibiotics%20used%20for%20non-medicinal%20purposes)
698

699 FAO, 2024. The State of World Fisheries and Aquaculture 2024 – Blue Transformation in action.
700 Rome. <http://doi.org/10.4060/cd0683en>
701

702 Farmer, J.J. III, Janda, J.M., Brenner, F.W., Cameron, D.N., Birkhead, K.M., 2005. Genus 1. *Vibrio*
703 *Pacini* 1854, 411AL. In: Brenner DJ, Krieg NR, Staley JT (eds) *Bergey's manual of systematic*
704 *bacteriology*, 2nd edn. The Proteobacteria part B. The Gammaproteobacteria. Springer, New York,
705 pp 494–546
706

707 Fečkaninová, A., Koščová, J., Mudroňová, D., Popelka, P., Toropilová, J., 2017. The use of probiotic
708 bacteria against *Aeromonas* infections in salmonid aquaculture. *Aquaculture* 469, 1–8.
709 <https://doi.org/10.1016/j.aquaculture.2016.11.042>
710

711 Firimino, J., Furones, M.D., Andree, K.B., Sarasquete, C., Ortiz-Delgado, J.B., Asencio-Alcudia, G.,
712 Gispert, E., 2019. Contrasting outcomes of *Vibrio harveyi* pathogenicity in gilthead seabream, *Sparus*
713 *aurata* and European seabass, *Dicentrarchus labrax*. *Aquaculture* 511, 734210.
714 <https://doi.org/10.1016/j.aquaculture.2019.734210>
715

716 Grimes, D.J., Gruber, S.H., May, E.B., 1985. Experimental infection of lemon sharks, *Negaprion*
717 *brevirostris* (Poey), with *Vibrio* species. *Journal of Fish Diseases* 8:173–180.
718 <https://doi.org/10.1111/j.1365-2761.1985.tb01212.x>
719

720 Guo, Y., Zhou, J., Tang, Y., Ma, Q., Zhang, J., Ji, C., Zhao, L., 2020. Characterization and genome
721 analysis of a zearalenone-degrading *Bacillus velezensis* strain ANSB01E. *Current Microbiology*
722 77:273–278. <https://doi.org/10.1007/s00284-019-01811-8>
723

724 Hrabar, J., Babić, I., Jozić, S., Trumbić, Ž., Pioppi, A., Nielsen, L.J.D., Maravić, A., Tomašević, T.,
725 Kovacs, Á.T., Mladineo, I., 2025. Prospecting microbiota of Adriatic fish: *Bacillus velezensis* as a
726 potential probiotic candidate. *Animal Microbiome* 7(1):64. [https://doi.org/10.1186/s42523-025-](https://doi.org/10.1186/s42523-025-00429-5)
727 [00429-5](https://doi.org/10.1186/s42523-025-00429-5)
728

729 Iannitti, T., Palmieri, B. 2010. Therapeutical use of probiotic formulations in clinical practice.
730 *Clinical Nutrition* 29, 701–725. <https://doi.org/10.1016/j.clnu.2010.05.004>
731

732 Ina-Salwany, M.Y., Al-Saari, N., Mohamad, A., Mursidi, F.A., Mohd-Aris, A., Amal, M.N.A., Kasai,
733 H., Mino, S., Sawabe, T., Zamri-Saad, M., 2019. Vibriosis in Fish: A Review on Disease
734 Development and Prevention. *Journal of Aquatic Animal Health* 31:3–22.
735 <https://doi.org/10.1002/aah.10045>
736

737 Islam, S.M.M., Rohani, Md F., Shahjahan, M.D., 2021. Probiotic yeast enhances growth performance
738 of Nile tilapia (*Oreochromis niloticus*) through morphological modifications of intestine.
739 Aquaculture Reports 21, 100800. <https://doi.org/10.1016/j.aqrep.2021.100800>
740

741 Khalid, F., Halid, A., Fu, Y., Hu, Q., Zheng, Y., Khan, S., Wang, Z., 2021. Potential of *Bacillus*
742 *velezensis* as a probiotic in animal feed: a review. Journal of Microbiology 59(7):627-633.
743 <https://doi.org/10.1007/s12275-021-1161-1>
744

745 Khan, A., Ghosh, K., 2013. Evaluation of phytase production by fish gut bacterium, *Bacillus subtilis*,
746 for processing of ipomea aquatica leaves as probable aquafeed ingredient, Journal of Aquatic Food
747 Product Technology 22, 508–519. <https://doi.org/10.1080/10498850.2012.669032>
748

749 Khojasteh, S.M.B., 2012. The morphology of the post-gastric alimentary canal in teleost fishes: a
750 brief review, International Journal of Aquatic Science 3, 71–88. [https://www.journal-](https://www.journal-aquaticscience.com/article_73560_aa8aabba2621b0eefe2b65afa5746ef2.pdf)
751 [aquaticscience.com/article_73560_aa8aabba2621b0eefe2b65afa5746ef2.pdf](https://www.journal-aquaticscience.com/article_73560_aa8aabba2621b0eefe2b65afa5746ef2.pdf)
752

753 Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., Glöckner, F.O., 2013.
754 Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation
755 sequencing-based diversity studies. Nucleic Acids Research, Volume 41, Issue 1, Page e1,
756 <https://doi.org/10.1093/nar/gks808>
757

758 Kuebutornye, F.A.K., Wang, Z., Lu, Y., Abarike, E.D., Sakyi, M.E., Li, Y., Xie, C.X., 2020. Effects
759 of three host-associated *Bacillus* species on mucosal immunity and gut health of Nile tilapia,
760 *Oreochromis niloticus* and its resistance against *Aeromonas hydrophila* infection. Fish and Shellfish
761 Immunology 97:83-95. <https://doi.org/10.1016/j.fsi.2019.12.046>
762

763 Korun, J., Timur, G., 2008. Marine vibrios associated with diseased sea bass (*Dicentrarchus labrax*)
764 in Turkey. Journal of Survey of Fisheries Science 2, 66-76.
765 <http://dx.doi.org/10.3153/jfscom.2008007>
766

767 Jacques, M., Aragon, V., Tremblay, Y.D.N., 2010. Biofilm formation in bacterial pathogens of
768 veterinary importance. Animal Health Research Reviews 11:97–121.
769 <https://doi.org/10.1017/s1466252310000149>
770

771 Lee, H.-J., Tran, M.T.H., Le, M.H., Justine, E.E., Kim, Y.-J., 2024. Paraprobiotic derived from
772 *Bacillus velezensis* GV1 improves immune response and gut microbiota composition in
773 cyclophosphamide-treated immunosuppressed mice. Frontiers in Immunology 15:1285063.
774 <https://doi.org/10.3389/fimmu.2024.1285063>
775

776 Li, J., Wu, Z.-B., Zhang, Z., Qu, S.-Y., Qi, X.-Z., Wang, G.-X., Ling, F., 2019. Effects of potential
777 probiotic *Bacillus velezensis* K2 on growth, immunity and resistance to *Vibrio harveyi* infection of
778 hybrid grouper (*Epinephelus lanceolatus* ♂ × *E. fuscoguttatus* ♀). Fish and Shellfish Immunology
779 93, 1047–1055. <https://doi.org/10.1016/j.fsi.2019.08.047>
780

781

782 Maechler, M., Rousseeuw, P., Struyf, A., Hubert, M., Hornik, K., 2025. cluster: Cluster Analysis
783 Basics and Extensions. R package version 2.1.6. <https://CRAN.R-project.org/package=cluster>
784

785 Martinez Arbizu, P., 2020. pairwiseAdonis: Pairwise multilevel comparison using Adonis. R package
786 version 0.4.1. <https://cran.r-project.org/web/packages/pairwise/index.html>
787

788 Meidong, R., Khotchanalekha, K., Doolgindachbaporn, S., Nagasawa, T., Nakao, M., Sakai, K.,
789 Tongpim, S., 2018. Evaluation of probiotic *Bacillus aerius* B81e isolated from healthy hybrid catfish
790 on growth, disease resistance and innate immunity of *Plamong Pangasius bocourti*, Fish and Shellfish
791 Immunology 73, 1–10. <https://doi.org/10.1016/j.fsi.2017.11.032>
792

793 Merrifield, D.L., Dimitroglou, A., Foey, A., Davies, S.J., Baker, R.T.M., Bøgwald, J., Castex, M.,
794 Ringø, E., 2010. The current status and future focus of probiotic and prebiotic applications for
795 salmonids. Aquaculture 302, 1–18. <http://dx.doi.org/10.1016/j.aquaculture.2010.02.007>
796

797 Mohamad, N., Amal, M.N.A., Yasin, I.S.M., Zamri Saad, M., Nasruddin, N.S., Al-saari, N., Mino,
798 S., Sawabe, T., 2019. Vibriosis in Cultured Marine Fishes: A Review. Aquaculture 512, 734289.
799 DOI: 10.1016/j.aquaculture.2019.734289
800

801 Monzón-Atienza, L., Bravo, J., Torrecillas, S., Montero, D., González-de Canales, A. F., García de
802 la Banda, I., Galindo-Villegas, J., Ramos-Vivas, J., Acosta, F., 2021. Isolation and Characterization
803 of a *Bacillus velezensis* D-18 strain, as a Potential Probiotic in European Seabass Aquaculture.
804 Probiotics and Antimicrobial Proteins 13:1404–1412. <https://doi.org/10.1007/s12602-021-09782-8>
805

806 Monzón- Atienza, L., Bravo, J., Fernández-Montero, A., Charlie-Silva, I., Montero, D., Ramos-
807 Vivas, J., Galindo-Villegas, J., Acosta, F., 2022. Dietary supplementation of *Bacillus velezensis*
808 improves *Vibrio anguillarum* clearance in European sea bass by activating essential innate immune
809 mechanisms. Fish and Shellfish Immunology 124, 244–253. <https://doi.org/10.1016/j.fsi.2022.03.032>
810

811 Monzón-Atienza, L., Bravo, J., Torrecillas, S., Gómez-Mercader, A., Montero, D., Ramos-Vivas, J.,
812 Galindo-Villegas, J., Acosta, F., 2024. An In-Depth Study on the Inhibition of Quorum Sensing by
813 *Bacillus velezensis* D-18: Its Significant Impact on *Vibrio* Biofilm Formation in Aquaculture.
814 Microorganisms 12(5):890. <https://doi.org/10.3390/microorganisms12050890>
815

816 Mougín, J., Roquigny, R., Flahaut, C., Bonnin-Jusserand, M., Grard, T., Le Bris, C., 2021. Abundance
817 and spatial patterns over time of Vibrionaceae and *Vibrio harveyi* in water and biofilm from a seabass
818 aquaculture facility. Aquaculture 542, 736862. <https://doi.org/10.1016/j.aquaculture.2021.736862>
819

820 Musella, M., Wathsala, R., Tavella, T., Rampelli, S., Barone, M., Palladino, G., Biagi, E., Brigidi, P.,
821 Turróni, S., Franzellitti, S., Candela, M., 2020. Tissue-scale microbiota of the Mediterranean mussel
822 (*Mytilus galloprovincialis*) and its relationship with the environment. Science of the Total
823 Environment 717. <https://doi.org/10.1016/j.scitotenv.2020.137209>
824

825 Neuwirth, E., 2022. RColorBrewer: ColorBrewer Palettes. R package version 1.1-3. [https://CRAN.R-](https://CRAN.R-project.org/package=RColorBrewer)
826 [project.org/package=RColorBrewer](https://CRAN.R-project.org/package=RColorBrewer)
827

828 Ntakirutimana, R., Syanya, F.J., Mwangi, P., 2023. Exploring the Impact of Probiotics on the Gut
829 Ecosystem and Morpho-Histology in Fish: Current Knowledge of Tilapia. Asian Journal of Fisheries
830 and Aquatic Research 25(3), pp.93-112. <https://doi.org/10.9734/ajfar/2023/v25i3670>
831

832 Oksanen, J., Blanchet, F.G., Friendly, M., De Cáceres, M., Legendre, P., McGlenn, D., Minchin, P.R.,
833 O’Hara, R.B., Simpson, G.L., Solymos, P., Stevens, M.H.H., Szoecs, E., Wagner, H., 2022. vegan:
834 Community Ecology Package. R package version 2.6-2. <https://CRAN.R-project.org/package=vegan>
835

836 Petit, C., Caudal, F., Taupin, L., Dufour, A., Le Ker, C., Giudicelli, F., Rodriguez, S., Bazire, A.,
837 2024. Antibiofilm Activity of the Marine Probiotic *Bacillus subtilis* C3 Against the

838 Aquaculture-Relevant Pathogen *Vibrio harveyi*. Probiotics and Antimicrobial Proteins 17:1551–
839 1562. <https://doi.org/10.1007/s12602-024-10229-z>
840

841 Pirarat, N., Pinpimai, K., Endo, M., Katagiri, T., Ponpornpisit, A., Chansue, N., Maita, M., 2011.
842 Modulation of intestinal morphology and immunity in Nile tilapia (*Oreochromis niloticus*) by
843 *Lactobacillus rhamnosus* GG. Research in Veterinary Science 91(3): e92-7.doi:
844 10.1016/j.rvsc.2011.02.014
845

846 Pujalte, M.J., Sitjà-Bobadilla, A., Macián, M.C., Belloch, C., Álvarez-Pellitero, P., Pérez-Sánchez,
847 J., Uruburu, F., Garay, E., 2003. Virulence and Molecular Typing of *Vibrio harveyi* Strains Isolated
848 from Cultured Dentex, Gilthead Sea Bream and European Sea Bass. Systemic and Applied
849 Microbiology 26, 284–292. <https://doi.org/10.1078/072320203322346146>
850

851 Quast, C., Klindworth, A., Pruesse, E., Schweer, T., Horn, M., Glo, F.O., 2013. Evaluation of general
852 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity
853 studies 41, 1–11. <https://doi.org/10.1093/nar/gks808>
854

855 Rahman, Md.A., Ashrafudoulla, Md., Akter, S., Park, S.H., Ha, S.D., 2023. Probiotics and biofilm
856 interaction in aquaculture for sustainable food security: A review and bibliometric analysis. Critical
857 Reviews in Food Science and Nutrition 1–17. <https://doi.org/10.1080/10408398.2023.2249114>
858

859 Ramos, M.A., Batista, S., Pires, M.A., Silva, A.P., Pereira, L.F., Saavedra, M.J., Ozório, R.O.A.,
860 Rema, P., 2017. Dietary probiotic supplementation improves growth and the intestinal morphology
861 of Nile tilapia. Animal 11, Issue 8, Pages 1259-1269. <https://doi.org/10.1017/S1751731116002792>
862

863 Rognes, T., Flouri, T., Nichols, B., Quince, C., Mahé, F., 2016. VSEARCH: A versatile open source
864 tool for metagenomics. PeerJ 2016, e2584. <https://doi.org/10.7717/peerj.2584>
865

866 Ruiz-García, C., Béjar, V., Martínez-Checa, F., Llamas, I., Quesada, E. 2005. *Bacillus velezensis* sp.
867 nov., a surfactant-producing bacterium isolated from the river Vélez in Málaga, southern Spain.
868 International Journal of Systematic Evolutionary Microbiology 55, 191–195.
869 <https://doi.org/10.1099/ijs.0.63310-0>
870

871 Salogni, C., Bertasio, C., Accini, A., Gibelli, L.R., Pigoli, C., Susini, F., Podavini, E., Scali, F.,
872 Varisco, G., Alborali, G.L., 2024. The Characterisation of *Lactococcus garvieae* Isolated in an
873 Outbreak of Septicaemic Disease in Farmed Sea Bass (*Dicentrarchus labrax*, Linnaeus 1758) in Italy.
874 Pathogens 13, no. 1: 49. <https://doi.org/10.3390/pathogens13010049>
875

876 Santos, L., Ramos, F., 2018. Antimicrobial resistance in aquaculture: Current knowledge and
877 alternatives to tackle the problem. International Journal of Antimicrobial Agents 52, 135–143.
878 <https://doi.org/10.1016/j.ijantimicag.2018.03.010>
879

880 Sarkar, P., Issac, P.K., Raju, S.V., Elumalai, P., Arshad, A., Arockiaraj, J., 2021. Pathogenic bacterial
881 toxins and virulence influences in cultivable fish. Aquaculture Research :1–16.
882 <http://dx.doi.org/10.1111/are.15089>
883

884 Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, E., Garrett, W. S., Huttenhower, C., 2011.
885 Metagenomic biomarker discovery and explanation. Genome Biology 12(6), R60.
886 <https://doi.org/10.1186/gb-2011-12-6-r60>
887

888 Smith, P., Cortinovis, L., Pretto, T., Manfrin, A., Florio, D., Fioravanti, M.L., Baron, S., Le
889 Devendec, L., Jouy, E., Le Breton, A., et al., 2023. Setting epidemiological cut-off values for *Vibrio*
890 *harveyi* relevant to MIC data generated by a standardised microdilution method. Diseases of Aquatic
891 Organisms 155, pp.35 - 42. <http://dx.doi.org/10.3354/dao03740>
892

893 Smyrli, M., Triga, A., Dourala, N., Varvarigos, P., Pavlidis, M., Quoc, V.H., Katharios, P., 2019.
894 Comparative Study on A Novel Pathogen of European Seabass. Diversity of *Aeromonas veronii* in
895 the Aegean Sea. Microorganisms 7, 504; <https://doi.org/10.3390/microorganisms7110504>
896

897 Tasneem, U., Yasin, N., Nisa, I., Shah, F., Rasheed, U., Momin, F., Zaman, S., Qasim, M., 2018.
898 Biofilm producing bacteria: a serious threat to public health in developing countries. Journal of Food
899 Science & Nutrition 01:25–31. <https://doi.org/10.35841/food-science.1.2.25-31>
900

901 Thurlow, C.M., Williams, M.A., Carrias, A., Ran, C., Newman, M., Tweedie, J., et al., 2019. *Bacillus*
902 *velezensis* AP193 exerts probiotic effects in channel catfish (*Ictalurus punctatus*) and reduces
903 aquaculture pond eutrophication, Aquaculture 503, 347–356,
904 <https://doi.org/10.1016/j.aquaculture.2018.11.051>
905

906 Tonetti, F.R., Eguielor, A., Llorente, C., 2024. Goblet cells: guardians of gut immunity and their role
907 in gastrointestinal diseases. eGastroenterology;2(3): e100098. <https://doi.org/10.1136/egastro-2024-100098>
908
909

910 Torres-Maravilla, E., Parra, M., Maisey, K., Vargas, R.A., Cabezas-Cruz, A., Gonzalez, A., Tello,
911 M., Bermúdez-Humarán, L.G., 2024. Importance of Probiotics in Fish Aquaculture: Towards the
912 Identification and Design of Novel Probiotics. Microorganisms 12, 626.
913 <https://doi.org/10.3390/microorganisms12030626>
914

915 Triga, A., Smyrli, M., Katharios, P., 2023. Pathogenic and Opportunistic *Vibrio* spp. Associated with
916 Vibriosis Incidences in the Greek Aquaculture: The Role of *Vibrio harveyi* as the Principal Cause of
917 Vibriosis. Microorganisms 11, 1197. <https://doi.org/10.3390/microorganisms11051197>
918

919 Vargas-Albores, F., Martínez-Cordova, L.R., Hernandez-Mendoza, A., Cicala, F., Lago-Leston, A.,
920 Martínez-Porchas, M., 2021. Therapeutic modulation of fish gut microbiota, a feasible strategy for
921 aquaculture? Aquaculture 544, 737050. <https://doi.org/10.1016/j.aquaculture.2021.737050>
922

923 Vazquez, F.J.S., Munoz-Cueto, J.A., 2014. Biology of European Sea Bass. CRC Press. 1st Edition.
924

925 Vendramin, N., Zrncic, S., Padros, F., Oraic, D., Le Breton, A., Zarza, C., Olesen, N.J., 2016. Fish
926 health in Mediterranean aquaculture past mistakes and future challenges. Workshop. Bulletin of the
927 European Association of Fish Pathologists 36, 38–45
928

929 Wang, C., Liu, Y., Sun, G., Li, X., Liu, Z., 2019. Growth, immune response, antioxidant capability,
930 and disease resistance of juvenile Atlantic salmon (*Salmo salar* L.) fed *Bacillus velezensis* V4 and
931 *Rhodotorula mucilaginosa* compound, Aquaculture 500, 65–74,
932 <https://doi.org/10.1016/j.aquaculture.2018.09.052>
933

934 Wood, T., 2025. RcppAlgos: High Performance Tools for Combinatorics. R package version 2.9.3.
935 <https://CRAN.R-project.org/package=RcppAlgos>
936

937 Ye, M., Tang, X., Yang, R., Zhang, H., Li, F., Tao, F., Li, F., Wang, Z. 2018. Characteristics and
938 application of a novel species of *Bacillus*: *Bacillus velezensis*. ACS Chemistry & Biology 13, 500–
939 505. <https://doi.org/10.1021/acscchembio.7b00874>
940

941 Yi, Y., Zhang, Z., Zhao, F., Liu, H., Yu, L., Zha, J., Wang, G., 2018. Probiotic potential of *Bacillus*
942 *velezensis* JW: antimicrobial activity against fish pathogenic bacteria and immune enhancement
943 effects on *Carassius auratus*, Fish and Shellfish Immunology 78, 322–330.
944 <https://doi.org/10.1016/j.fsi.2018.04.055>
945

946 Zhang, X.-H., He, X., Austin, B., 2020. *Vibrio harveyi*: a serious pathogen of fish and invertebrates
947 in mariculture. Marine Life Science & Technology <https://doi.org/10.1007/s42995-020-00037-z>
948

949 Zoli, M., Rossi, L., Bibbiani, C., Bacenetti J., 2023. Life cycle assessment of seabass and seabream
950 production in the Mediterranean area: A critical review. Aquaculture 573, 739580.
951 <https://doi.org/10.1016/j.aquaculture.2023.739580>
952

953
954
955

Supplementary tables

Supplementary Table 1				
<i>Mean relative abundance and standard deviation of the most abundant phyla in gut</i>				
	Ctrl	Ctrl-Bv	Ctrl-Ch	Ctrl-Bv-Ch
Pseudomonadota	39.09 ± 6.37	8.63 ± 9.13	2.29 ± 1.85	36.56 ± 17.69
Bacillota	23.36 ± 6.84	28.69 ± 32.66	58.61 ± 52.51	27.05 ± 20.67
Bacteroidota	17.46 ± 1.51	0.65 ± 1.14	0.25 ± 0.35	2.57 ± 2.62
Actinomycetota	6.23 ± 8.81	1.26 ± 1.52	1.39 ± 1.97	1.47 ± 2.14
Spirochaetota	5.901 ± 8.35	59.95 ± 35.92	36.64 ± 51.82	27.92 ± 43.22

956
957

Supplementary Table 2				
<i>Mean relative abundance and standard deviation of the most abundant phyla in biofilm</i>				
	Ctrl	Ctrl-Bv	Ctrl-Ch	Ctrl-Bv-Ch
Bacteroidota	31.69 ± 3.21	44.59 ± 5.12	20.22 ± 7.85	36.56 ± 6.99
Pseudomonadota	31.36 ± 3.34	26.56 ± 5.67	40.16 ± 12.94	31.42 ± 9.55
Chloroflexota	13.005 ± 0.34	10.87 ± 5.52	13.77 ± 9.94	14.81 ± 10.19
Verrucomicrobiota	9.72 ± 0.41	4.37 ± 0.66	2.078 ± 1.27	4.09 ± 3.69
Planctomycetota	9.02 ± 2.54	2.62 ± 0.86	11.53 ± 4.55	4.04 ± 2.35

958
959

Supplementary Table 3				
<i>Mean relative abundance and standard deviation of the most abundant families in gut</i>				
	Ctrl	Ctrl-Bv	Ctrl-Ch	Ctrl-Bv-Ch
<i>Enterobacteriaceae</i>	16.23 ± 22.95	0.82 ± 1.42	0 ± 0	8.85 ± 15.33
<i>Alicyclobacillaceae</i>	10.25 ± 7.53	1.202 ± 2.08	0 ± 0	0 ± 0
<i>Flavobacteriaceae</i>	8.77 ± 3.13	0.66 ± 1.14	0 ± 0	2.02 ± 2.82
<i>Saprospiraceae</i>	6.06 ± 3.48	0 ± 0	0 ± 0	0 ± 0
<i>Spirochaetaceae</i>	5.90 ± 8.35	59.95 ± 35.92	36.64 ± 51.82	27.92 ± 43.22
<i>Lactobacillaceae</i>	4.59 ± 6.49	1.64 ± 1.43	6.15 ± 8.69	1.80 ± 3.12
<i>Streptococcaceae</i>	4.02 ± 5.68	12.95 ± 15.99	31.80 ± 16.69	12.68 ± 3.12
<i>Vibrionaceae</i>	0 ± 0	4.37 ± 4.01	0 ± 0	0 ± 0
<i>Pseudomonadaceae</i>	0 ± 0	0 ± 0	0 ± 0	15.96 ± 15.74
<i>Lachnospiraceae</i>	0 ± 0	9.62 ± 16.66	19.92 ± 28.17	4.97 ± 8.61

960
961

Supplementary Table 4				
<i>Mean relative abundance and standard deviation of the most abundant families in biofilm</i>				
	Ctrl	Ctrl-Bv	Ctrl-Ch	Ctrl-Bv-Ch
<i>Chitinophagaceae</i>	0.38 ± 0.34	6.39 ± 3.78	0.16 ± 0.28	0.27 ± 0.47
<i>Flavobacteriaceae</i>	16.61 ± 1.33	10.82 ± 5.36	14.59 ± 7.20	19.29 ± 16.37
<i>Hyphomonadaceae</i>	2.51 ± 0.76	1.91 ± 1.90	4.37 ± 2.05	4.43 ± 1.89
<i>Paracoccaceae</i>	12.08 ± 1.16	7.98 ± 3.93	10.66 ± 3.04	7.81 ± 0.34
<i>Pirellulaceae</i>	6.77 ± 1.95	1.31 ± 0.71	4.81 ± 1.47	2.08 ± 0.19
<i>Rubritaleaceae</i>	9.62 ± 0.25	4.37 ± 0.66	1.80 ± 1.40	3.72 ± 4.09
<i>Saprospiraceae</i>	9.89 ± 2.83	21.86 ± 3.79	2.89 ± 0.58	13.61 ± 10.05

962